AML Epigenomic Risk remained as an independent predictor of OS (HR=3.86; 95% CI=2.74, 5.44; P<0.0001) (Figure 3C) and EFS (HR=1.78; 95% CI=1.40, 2.27; P=0.0009) (Figure 3D) in multivariable analysis after adjusting for MRD1 status, risk group, FLT3 status, leucocyte counts at diagnosis, BM blast % at diagnosis, and age groups in discovery cohort. Here, FLT3 is linked to acute myeloid leukemia.